active ingredient: 1 ml of solution contains phosphatidylcholine from soya beans 50 mg;
excipients: benzyl alcohol, deoxycholic acid, sodium chloride, sodium hydroxide, riboflavin (E 101), water for injection.
Dosage form. Injection.
Main physicochemical properties: clear yellow solution.
Hepatotropic drugs. ATX code A05B A.
In diseases of the liver, hepatocyte membranes and their organelles are always damaged, which can lead to changes in the activity of membrane-bound enzymes and receptor systems, disruption of the metabolic function of the cell and a decrease in the intensity of regeneration of the liver.
The phospholipids contained in the preparation Lesfal are similar in their chemical structure to endogenous phospholipids, but far outweigh them due to the high content of polyunsaturated (essential) fatty acids. These high-energy molecules are incorporated predominantly into the cell membrane structures and facilitate the repair of damaged liver tissue. Since the cis-double bonds of these polyene acids interfere with the parallel arrangement of the hydrocarbon chains of membrane phospholipids, the density of the arrangement of phospholipid structures decreases, with the result that the rate of entry and elimination of substances increases. Membrane-bound enzymes form functional units that can enhance their activity and ensure the physiological course of the main metabolic processes. Phospholipids affect impaired lipid metabolism by regulating lipoprotein metabolism, resulting in neutral fats and cholesterol being converted into forms suitable for transport, especially due to the increased ability of high-density lipoprotein (HDL) to add cholesterol, and sent for further oxidation. During phospholipid excretion through the biliary tract, the lithogenic index decreases and bile stabilizes.
When taken orally, more than 90% of the drug is absorbed in the small intestine. The main amount is cleaved by phospholipase A to 1-acyl-lyso-phosphatidylcholine, 50% of which is immediately reacetylated to polyunsaturated phosphatidylcholine during absorption in the small intestine. Polyunsaturated phosphatidylcholine with a current of lymph enters the blood and from there, mainly in combination with HDL, is transported to the liver. The maximum content of phosphatidylcholine in the blood after 6-24 hours after oral administration is an average of 20%.
The half-life of the choline component is 66 hours, for saturated fatty acids - 32 hours.
In the course of kinetic studies in the human body, less than 5% of each of the 3H and 14C isotopes introduced was excreted with feces.
Non-alcoholic steatohepatitis, alcoholic steatohepatitis, acute and chronic hepatitis of various etiologies, liver cirrhosis, pre- and postoperative treatment of liver and biliary tract surgery, toxicosis of pregnant women, psoriasis, radiation syndrome.
Hypersensitivity to any of the components of the drug.
Lesfal should not be prescribed to newborns and premature babies, since benzyl alcohol is a part of the drug.
Interaction with other drugs and other types of interactions.
Do not use electrolyte solutions for dilution of the drug.
When breeding Lesfal for the preparation of infusion solutions (if it is impossible to use the patient’s own blood), electrolyte-free solutions should be used, namely: 5% or 10% glucose solution (1: 1 ratio), 5% xylitol solution.
Use only clear solution.
The drug is incompatible with electrolyte solutions (physiological sodium chloride solution, Ringer's solution, etc.).
You can not mix in the same syringe with other drugs.
Caution: the solution contains alcohol 5.02 mg / ml.
1 ml of the drug Lesfal contains 0.1 mmol of sodium. When taking the drug in a dose of 10 ml of sodium is 1.0 mmol (25.8 mg), which should be taken into account by patients who are on a sodium - controlled diet.
For intravenous use only. The drug should be administered slowly.
Lesfal's solution should not be injected into the muscles (intramuscularly), as this can lead to local irritation.
Use during pregnancy or lactation.
Due to the limited number of clinical studies on the use of pregnant women and because of the presence of benzyl alcohol in the composition, which can pass through the placental barrier, the use of Lesfal is not recommended during pregnancy or breastfeeding.
The ability to influence the reaction rate when driving vehicles or other mechanisms.